Correction: Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)?

• by Kumaresan Sandrasegaran, Amar S. Shah, Cole P. Thompson, Channa R. Jayasekera, Elizabeth J. Carey, Ayana Jain, Aubrey N. Silva, Suhaas R. Bonkur, Anshuman J. Panda, Sudhakar K. Venkatesh, Alvin C. Silva

• September 30, 2026

Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

• September 30, 2026

• 1 min

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

• by

• September 24, 2026

• 11 min

Microbiological quality of bread and identification of critical contamination points along the production chain in Ouagadougou, Burkina Faso

• by Nafissatou Ouédraogo, Serge Samandoulougou, Hadiza Bawa Ibrahim, Judith Pascaline Koalaga, Soutongnooma Caroline Bouda, René Dembélé, Nicolas Barro

• October 1, 2026